Meta Analysis of Shuxuetong Injection Combined with Ozagrel Sodium in Treatment of Acute Cerebral Infarction

WANG Li-mei; LIU Xing-mei; YAO Ming; FU Xiu-juan; JIN Xiang-qun

doi:10.11653/syfj2013200319

您当前的位置：

首页 >

文章列表页 >

Meta Analysis of Shuxuetong Injection Combined with Ozagrel Sodium in Treatment of Acute Cerebral Infarction

更新时间：2024-01-04

- Meta Analysis of Shuxuetong Injection Combined with Ozagrel Sodium in Treatment of Acute Cerebral Infarction
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 19, Issue 20, Pages: 319-324(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.11653/syfj2013200319
  CLC：
- Published：2013
- 稿件说明：
移动端阅览
WANG Li-mei, LIU Xing-mei, YAO Ming, et al. Meta Analysis of Shuxuetong Injection Combined with Ozagrel Sodium in Treatment of Acute Cerebral Infarction[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(20): 319-324.
DOI：

WANG Li-mei, LIU Xing-mei, YAO Ming, et al. Meta Analysis of Shuxuetong Injection Combined with Ozagrel Sodium in Treatment of Acute Cerebral Infarction[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(20): 319-324. DOI： 10.11653/syfj2013200319.

摘要

目的: 评价奥扎格雷钠联合疏血通注射液治疗急性脑梗死的疗效和安全性。方法: 通过计算机在线检索已经公开发表的关于奥扎格雷钠联合疏血通注射液治疗急性脑梗死的临床随机对照试验的相关文献

结合纳入文献中两组的总有效率、神经功能缺损评分等数据

并应用Review Manager 5.1.7做Meta分析。结果: 共纳入24个随机对照试验。分析显示

奥扎格雷钠联合疏血通注射液治疗急性脑梗死的神经功能缺损临床疗效比值比(OR)合并值为4.30(95%可信区间为3.16~5.86)。神经功能缺损评分疗效加权均数差(WMD)合并值为-3.63(95%可信区间为-4.85~-2.41)。结论: 奥扎格雷钠联合疏血通注射液治疗急性脑梗死临床疗效确切

未见明显不良反应

但仍需要更多严格、多中心的随机双盲对照试验提供有力证据。

Abstract

Objective: It is to assess the curative effect and safety of Shuxuetong injection combined with Ozagrel Sodium injection in the treatment of acute cerebral infarction(ACI) with Meta analysis method. Method: The randomized controlled clinical trials of Shuxuetong injection combined with Ozagrel Sodium injection for the treatment of ACI from 1989-2012 were searched by computer-based on line search

and the data was statistically analyzed by Review Manager 5.1.7. Result: The results showed that there were 24 literatures which incorporated by Meta-analysis and the criterion were homogenous. Fixed effect model statistics and analysis showed that the OR(95%CI)was 4.30(3.16-5.86). WMD(95%CI)was-3.63(-4.85--2.41). Conclusion: Meta analysis shows that Shuxuetong combined with Ozagrel Sodium injection is effective for ACI and it can improve the clinlcal symptom and neurologic impairment in the treatment of ACI without obvious ADR. However

more strict and multicentric randomized double-blind control trials are needed in order to provide more convinced evidence.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Systematic Review of Ozagrel Sodium Combined with Shuxuening Injection in Treatment of Acute Cerebral in Farction

Clinical Efficacy of Shuxuetong Injection Plus Buyang Huanwutang for Treating Acute Cerebral Infarction (Qixu Xueyu) 56 Ptients

Clinical Observation on Shuxuetong Injection in Treatment of Patients with Acute Cerebral Infarction

Effect of Tongnaoyin on Cerebral Hemodynamics in Patients with Acute Cerebral Infarction of Phlegm and Blood Stasis Syndrome Based on CTA/CTP

Meta-analysis of Distribution Frequency of Traditional Chinese Medicine Syndrome in Primary Osteoporosis

Related Author

CHAI Jin

LI Jin-dong

ZHU Da-sheng

SHI Chun-shan

FU Xiu-juan

WANG Heng

SHI Zhi-qin

ZHANG Han-xin

Related Institution

The Affiliated Hospital of Nanjing University of Chinese Medicine/ Jiangsu Province Hospital of Chinese Medicine

Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

Affiliated Hospital of Changchun University of Chinese Medicine

Evidence-based Medicine Center，Changchun University of Chinese Medicine

Changchun University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰